Macrogenics Stock Today
| MGNX Stock | USD 1.37 0.03 2.14% |
PerformanceWeakest
| Odds Of DistressStrong
|
MacroGenics is trading at 1.37 as of the 15th of December 2025; that is 2.14 percent decrease since the beginning of the trading day. The stock's open price was 1.4. MacroGenics has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 18th of June 2025 and ending today, the 15th of December 2025. Click here to learn more.
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. The company was incorporated in 2000 and is headquartered in Rockville, Maryland. Macrogenics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 63.26 M outstanding shares of which 3.61 M shares are now shorted by private and institutional investors with about 4.09 trading days to cover. More on MacroGenics
Moving against MacroGenics Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
MacroGenics Stock Highlights
| CEO President | Scott MD |
| Thematic Idea | Cancer Fighters (View all Themes) |
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Composite Total, NASDAQ Biotechnology, Cancer Fighters, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) |
| Financial Strength | |
MacroGenics (MGNX) is traded on NASDAQ Exchange in USA and employs 341 people. MacroGenics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 88.56 M. MacroGenics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 63.26 M outstanding shares of which 3.61 M shares are now shorted by private and institutional investors with about 4.09 trading days to cover.
MacroGenics currently holds about 133.74 M in cash with (68.37 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.18, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check MacroGenics Probability Of Bankruptcy
Ownership AllocationMacroGenics maintains a total of 63.26 Million outstanding shares. The majority of MacroGenics outstanding shares are owned by institutional investors. These third-party entities are usually referred to as non-private investors looking to shop for positions in MacroGenics to benefit from reduced commissions. Consequently, institutional holders are subject to a different set of regulations than regular investors in MacroGenics. Please pay attention to any change in the institutional holdings of MacroGenics as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check MacroGenics Ownership Details
MacroGenics Risk Profiles
Investors will always prefer to have the highest possible return on investment while minimizing volatility. MacroGenics market risk premium is the additional return an investor will receive from holding MacroGenics long position in a well-diversified portfolio.
| Mean Deviation | 3.6 | |||
| Semi Deviation | 4.12 | |||
| Standard Deviation | 4.79 | |||
| Variance | 22.91 |
MacroGenics Stock Against Markets
MacroGenics Corporate Management
| Eric Risser | Sr. VP of Bus. Devel. and Portfolio Management | Profile | |
| Beth Smith | Controller VP | Profile | |
| Steve Harig | Senior Resources | Profile | |
| Christopher MD | VP Communications | Profile | |
| Harish Krishnaswamy | Senior Planning | Profile | |
| Ezio MD | Senior Officer | Profile |
Additional Tools for MacroGenics Stock Analysis
When running MacroGenics' price analysis, check to measure MacroGenics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MacroGenics is operating at the current time. Most of MacroGenics' value examination focuses on studying past and present price action to predict the probability of MacroGenics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MacroGenics' price. Additionally, you may evaluate how the addition of MacroGenics to your portfolios can decrease your overall portfolio volatility.